Therefore, it is necessary to conduct a comprehensive economic evaluation of targeted drugs for PAH not only limited to ERA and PDE5i but also sGCs, prostacyclin analogs, and prostacyclin receptor agonists to provide a more comprehensive reference for clinical decision- and policy-making. Here, PTGIR is linked to pulmonary arterial hypertension.